letters & comments

NHC Comments on Patient-Focused Drug Development: Methods to Identify What Is Important to Patients; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders

12/18/2019

Read More

NHC Comments on Congressional Efforts to Address Drug Pricing

12/17/2019

Read More

Letter to Representatives DeGette & Upton on the “Cures 2.0” Initiative

12/16/2019

Read More

NHC Comments on Proposed Changes to ICER’s 2020 Framework

10/18/2019

Read More

NHC Comments on CY 2020 Revisions to Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment Policies

09/27/2019

Read More

NHC Comments on Proposed Changes to the Medicare Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System

09/27/2019

Read More

NHC Comments on Value Assessment Methods for Single or Short-Term Transformative Therapies (SSTs)

09/06/2019

Read More

NHC Comments on CMS Request for Information: Reducing Administrative Burden to Put Patients over Paperwork

08/13/2019

Read More

NHC Comments on FDA’s Draft Guidance on Enhancing the Diversity of Clinical Trial Populations

08/06/2019

Read More
1 2 3 4 5 6